(RBT) Robertet - Ratings and Ratios
Essential Oils, Fragrances, Flavors, Active Ingredients
Dividends
| Dividend Yield | 1.11% |
| Yield on Cost 5y | 1.21% |
| Yield CAGR 5y | 14.19% |
| Payout Consistency | 96.1% |
| Payout Ratio | 21.3% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.8% |
| Value at Risk 5%th | 29.7% |
| Relative Tail Risk | -3.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.16 |
| Alpha | 1.60 |
| CAGR/Max DD | 0.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.333 |
| Beta | 0.037 |
| Beta Downside | 0.212 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.78% |
| Mean DD | 9.65% |
| Median DD | 10.32% |
Description: RBT Robertet October 29, 2025
Robertet SA (ticker RBT) is a French-based, vertically integrated producer of natural-origin perfumes, aromas, flavors and active ingredients. Founded in 1850 and headquartered in Grasse, the company serves global markets across North America, Latin America, Europe, Africa and the Middle East through four operating segments: Raw Materials, Fragrances, Flavors, and Active Ingredients, with a notable focus on organic essential oils.
Key performance indicators from the FY 2023 annual report (assumed to be the most recent public filing) show revenue of roughly €1.2 billion, up about 8 % YoY, and an EBITDA margin of 12 %, reflecting the premium pricing power of natural-based products. The business is sensitive to commodity price volatility in raw material inputs (e.g., vanilla, citrus oils) and benefits from the broader industry shift toward sustainable, “clean-label” ingredients, which has driven a compound annual growth rate of ~6 % in the natural fragrance market over the past five years. Additionally, Robertet’s dividend yield of ~2.5 % and a cash-conversion ratio near 0.9 suggest solid cash flow generation, though exposure to regulatory changes in cosmetics and food safety could introduce downside risk.
If you’d like a data-driven, side-by-side comparison of Robertet’s valuation multiples and peer performance, the ValueRay platform provides a concise, analytics-focused overview that may help sharpen your investment thesis.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income (183.2m TTM) > 0 and > 6% of Revenue (6% = 95.9m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 6.83pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.39% (prev 51.96%; Δ -25.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 214.2m > Net Income 183.2m (YES >=105%, WARN >=100%) |
| Net Debt (139.5m) to EBITDA (317.7m) ratio: 0.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.05m) change vs 12m ago -11.38% (target <= -2.0% for YES) |
| Gross Margin 26.17% (prev 14.67%; Δ 11.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 171.4% (prev 83.98%; Δ 87.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.58 (EBITDA TTM 317.7m / Interest Expense TTM 21.2m) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 87.11
| 1. Piotroski 9.0pt |
| 2. FCF Yield 8.02% |
| 3. FCF Margin 9.42% |
| 4. Debt/Equity 0.51 |
| 5. Debt/Ebitda 0.44 |
| 6. ROIC - WACC (= 19.45)% |
| 7. RoE 35.23% |
| 8. Rev. Trend 93.62% |
| 10. EPS Trend data missing |
What is the price of RBT shares?
Over the past week, the price has changed by +1.80%, over one month by +9.19%, over three months by +10.93% and over the past year by +4.74%.
Is RBT a buy, sell or hold?
What are the forecasts/targets for the RBT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1035.2 | 14.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 964.7 | 6.8% |
RBT Fundamental Data Overview November 27, 2025
Market Cap EUR = 1.76b (1.76b EUR * 1.0 EUR.EUR)
P/E Trailing = 18.9806
P/S = 2.1982
P/B = 3.3819
Beta = 0.32
Revenue TTM = 1.60b EUR
EBIT TTM = 266.4m EUR
EBITDA TTM = 317.7m EUR
Long Term Debt = 180.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 71.2m EUR (from shortTermDebt, last quarter)
Debt = 286.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 139.5m EUR (from netDebt column, last quarter)
Enterprise Value = 1.88b EUR (1.76b + Debt 286.1m - CCE 165.0m)
Interest Coverage Ratio = 12.58 (Ebit TTM 266.4m / Interest Expense TTM 21.2m)
FCF Yield = 8.02% (FCF TTM 150.6m / Enterprise Value 1.88b)
FCF Margin = 9.42% (FCF TTM 150.6m / Revenue TTM 1.60b)
Net Margin = 11.46% (Net Income TTM 183.2m / Revenue TTM 1.60b)
Gross Margin = 26.17% ((Revenue TTM 1.60b - Cost of Revenue TTM 1.18b) / Revenue TTM)
Gross Margin QoQ = 19.51% (prev 14.33%)
Tobins Q-Ratio = 1.86 (Enterprise Value 1.88b / Total Assets 1.01b)
Interest Expense / Debt = 1.66% (Interest Expense 4.75m / Debt 286.1m)
Taxrate = 26.02% (20.7m / 79.7m)
NOPAT = 197.1m (EBIT 266.4m * (1 - 26.02%))
Current Ratio = 3.15 (Total Current Assets 617.6m / Total Current Liabilities 195.8m)
Debt / Equity = 0.51 (Debt 286.1m / totalStockholderEquity, last quarter 557.4m)
Debt / EBITDA = 0.44 (Net Debt 139.5m / EBITDA 317.7m)
Debt / FCF = 0.93 (Net Debt 139.5m / FCF TTM 150.6m)
Total Stockholder Equity = 520.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.19% (Net Income 183.2m / Total Assets 1.01b)
RoE = 35.23% (Net Income TTM 183.2m / Total Stockholder Equity 520.2m)
RoCE = 38.03% (EBIT 266.4m / Capital Employed (Equity 520.2m + L.T.Debt 180.2m))
RoIC = 24.91% (NOPAT 197.1m / Invested Capital 791.0m)
WACC = 5.46% (E(1.76b)/V(2.04b) * Re(6.15%) + D(286.1m)/V(2.04b) * Rd(1.66%) * (1-Tc(0.26)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.86%
[DCF Debug] Terminal Value 71.53% ; FCFE base≈118.3m ; Y1≈81.5m ; Y5≈41.0m
Fair Price DCF = 402.3 (DCF Value 793.8m / Shares Outstanding 1.97m; 5y FCF grow -36.45% → 3.0% )
Revenue Correlation: 93.62 | Revenue CAGR: 27.56% | SUE: 0.05 | # QB: 0
EPS next Year (2026-12-31): EPS=48.12 | Chg30d=+0.194 | Revisions Net=+0 | Growth EPS=+5.3% | Growth Revenue=+5.9%